Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Finance Committee Plans Hearing On Medicare Rx Implementation

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS Administrator Mark McClellan will testify at Sept. 14 hearing to discuss implementing the Medicare drug benefit and Medicare Advantage program. Other witness include PCMA President Mark Merritt and AHIP President Karen Ignagni.

You may also be interested in...



Medicare Rx Hearings Planned For Senate Committee On Aging

Sen. Craig wants to "keep CMS on its toes" as it implements the Medicare drug benefit. Craig holds press briefing to discuss the benefits of Medicare Modernization Act on the same day as President Bush's nomination acceptance speech.

Medicare Rx Implementing Regs Open For Comment Until October

Proposed rules for Title I (Part D drug benefit) and Title II (Medicare Advantage) of the Medicare Modernization Act are unveiled at an HHS press conference. Final regs will be done by early 2005, "if not sooner," CMS Administrator McClellan says.

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel